{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihij7jm6vsisldo3yi53cinw5jlbidh6z622ixndjcnfgdtfn62vq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mhvhmx7kv2m2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigzs2u4z5h7ctp5epifzua47b5gsbk2cvd2jk2mheqesgepyjwpoq"
    },
    "mimeType": "image/jpeg",
    "size": 97606
  },
  "path": "/2026/03/25/sarepta-therapeutics-fshd-dm1-study-results/?utm_campaign=rss",
  "publishedAt": "2026-03-25T14:28:25.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "drug development",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "Sarepta Therapeutics’ next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said.",
  "title": "STAT+: Sarepta Therapeutics shares rise on early promise for rare disease drugs",
  "updatedAt": "2026-03-25T14:59:44.000Z"
}